Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

Oncologist

Volumn 18, Issue 11, 2013, Pages 1214-1220

  Goldberg, Sarah B ^a,b   Oxnard, Geoffrey R ^b,c,d   Digumarthy, Subba ^b,e   Muzikansky, Alona ^b,e   Jackman, David M ^b,c,d   Lennes, Inga T ^a,b   Sequist, Lecia V ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug resistance; Epidermal growth factor receptor; Non small cell lung cancer; Protein kinase inhibitor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

DRUG RESISTANCE; EPIDERMAL GROWTH FACTOR RECEPTOR; NON-SMALL CELL LUNG CANCER; PROTEIN KINASE INHIBITOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84887434792     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0168     Document Type: Article

References (34)

1. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
2. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
5. Oxnard GR, Arcila ME, Chmielecki J et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17: 5530-5537.
6. Chmielecki J, Foo J, Oxnard GR et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59.
7. Chaft JE, Oxnard GR, Sima CS et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res 2011;17:6298-6303.
8. Riely GJ, Kris MG, Zhao B et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13: 5150-5155.
9. Extra JM, Antoine EC, Vincent-Salomon A et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: The observational Hermine study. The Oncologist 2010;15:799-809.
10. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
11. National Comprehensive Cancer Network: Non-Small Cell Lung Cancer, Version 3. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed September 9, 2013.
12. Oxnard GR, Arcila ME, Sima CS et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring theT790Mmutation. Clin Cancer Res 2011;17:1616-1622.
13. Goldstraw P, Crowley J, Chansky K et al. The IASLCLungCancerStaging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
14. Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall- cell lung cancer. J Clin Oncol 2010;28:357-360.
15. Oxnard GR, Janjigian YY, Arcila ME et al. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res 2011;17: 6322-6328.
16. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-1180.
17. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. J Clin Oncol 1982;5:649-655.
19. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2: 146-158.
20. Sequist LV, Joshi VA, Janne PA et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006;12: 4403s-4408s.
21. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
22. Blackhall F, Ranson M, Thatcher N. Wherenext for gefitinib in patients with lung cancer? LancetOncol 2006;7:499-507.
23. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
24. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
25. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
26. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
27. Jänne PA, Wang X, Socinski MA et al. Randomized phase II trial of erlotinib alone or with carboplatinandpaclitaxel in patientswhowerenever or light former smokers with advanced lung adenocarcinoma: CALGB 30406 Trial. J Clin Oncol 2012;30:2063-2069.
28. Hirsch FR, Kabbinavar F, Eisen T et al. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011;29: 3567-3573.
29. Riely GJ, Rizvi NA, Kris MG et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:264-270.
30. Wu Y-L, Lee JS, Thongprasert S et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, doubleblind trial. Lancet Oncol 2013;14:777-786.
31. Aerts JG, Codrington H, Burgers S et al. A randomized phase II study comparing erlotinib (E) versus E alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 study. Ann Oncol 2013 August 28 [Epub ahead of print].
32. Yoshimura N, Okishio K, Mitsuoka S et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol 2013;8:96-101.
33. Halmos B, Pennell NA, Otterson GA et al. Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. J Clin Oncol 2013;31 (suppl):abstr 8114.
34. Wu JY, Shih JY, Yang CH et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010;126:247-255.